Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.54 |
| ▸ | ESR1 | P03372 | 4/20 | 0.51 |
| ▸ | WIZ | O95785 | 2/20 | 0.51 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.48 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.48 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30906292 | 0.94 | CRBN (0.57) | CRBNESR1WIZIKZF1IKZF2 | |
| SCHEMBL30906245 | 0.94 | ESR1 (0.53) | CRBNESR1WIZIKZF1CSNK1A1 | |
| SCHEMBL30889706 | 0.93 | CRBN (0.51) | CRBNESR1WIZIKZF1CSNK1A1 | |
| SCHEMBL30822427 | 0.93 | CRBN (0.54) | CRBNESR1WIZGSPT1IKZF3 | |
| SCHEMBL24734974 | 0.91 | CRBN (0.51) | CRBNESR1WIZIKZF1CSNK1A1 | |
| SCHEMBL30822432 | 0.90 | CRBN (0.52) | CRBNESR1WIZIKZF1CSNK1A1 | |
| SCHEMBL24734992 | 0.90 | CRBN (0.52) | CRBNESR1WIZIKZF1CSNK1A1 | |
| SCHEMBL29841236 | 0.90 | CRBN (0.52) | CRBNESR1WIZIKZF1CSNK1A1 | |
| SCHEMBL25373583 | 0.90 | CRBN (0.50) | CRBNESR1WIZIKZF1CSNK1A1 | |
| SCHEMBL30822421 | 0.90 | CRBN (0.53) | CRBNESR1WIZIKZF1CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598905-A2 | CEREBLON-RECRUITING BCL-XL/BCL-2 DUAL DEGRADERS | University of Florida Research Foundation, Incorporated (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250082762-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-03-13 | — | — | US | disclosed |
| US-20250073341-A1 | BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-03-06 | — | — | US | disclosed |
| US-12161722-B2 | Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-12-10 | — | — | US | disclosed |
| US-20240285778-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-29 | — | — | US | disclosed |
| EP-4361153-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024077023-A2 | CEREBLON-RECRUITING BCL-XL/BCL-2 DUAL DEGRADERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| WO-2023088385-A1 | COMPOUND FOR DEGRADING EGFR PROTEIN AND USE THEREOF | 浙江同源康医药股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2022012622-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | CRBN 144/4885ESR1 1044/4885WIZ 2241/4885 |
| US-20250073341-A1 | BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | BTK, XIAP, SYK | CRBN 129/4885ESR1 3011/4885WIZ 687/4885 |
| US-20250082762-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | BTK, XIAP, UBE3C | CRBN 138/4885ESR1 3120/4885WIZ 795/4885 |
| US-12161722-B2 | Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof | BTK, XIAP, SYK | CRBN 129/4885ESR1 3011/4885WIZ 687/4885 |
| US-20240285778-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | BTK, XIAP, UBE3C | CRBN 138/4885ESR1 3120/4885WIZ 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.